Skip to main navigation Skip to search Skip to main content

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer

  • Jing Guo
  • , Chunyan Wang
  • , Ning Luo
  • , Yuliang Wu
  • , Wei Huang
  • , Jihui Zhu
  • , Weihui Shi
  • , Jinye Ding
  • , Yao Ge
  • , Chunhong Liu
  • , Zhen Lu
  • , Robert C. Bast
  • , Guihai Ai
  • , Weihong Yang
  • , Rui Wang
  • , Caixia Li
  • , Rong Chen
  • , Shupeng Liu
  • , Huajun Jin
  • , Binghui Zhao
  • Zhongping Cheng

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Tumor-infiltrating lymphocyte (TIL) therapy has been restricted by intensive lymphodepletion and high-dose intravenous interleukin-2 (IL-2) administration. To address these limitations, we conducted preclinical and clinical studies to evaluate the safety, antitumor activity, and pharmacokinetics of an innovative modified regimen in patients with advanced gynecologic cancer. Methods: Patient-derived xenografts (PDX) were established from a local recurrent cervical cancer patient. TILs were expanded ex vivo from minced tumors without feeder cells in the modified TIL therapy regimen. Patients underwent low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2. The primary endpoint was safety; the secondary endpoints included objective response rate, duration of response, and T cell persistence. Results: In matched patient-derived xenografts (PDX) models, homologous TILs efficiently reduced tumor size (p < 0.0001) and underwent IL-2 absence in vivo. In the clinical section, all enrolled patients received TIL infusion using a modified TIL therapy regimen successfully with a manageable safety profile. Five (36%, 95% CI 16.3–61.2) out of 14 evaluable patients experienced objective responses, and three complete responses were ongoing at 19.5, 15.4, and 5.2 months, respectively. Responders had longer overall survival (OS) than non-responders (p = 0.036). Infused TILs showed continuous proliferation and long-term persistence in all patients and showed greater proliferation in responders which was indicated by the Morisita overlap index (MOI) of TCR clonotypes between infused TILs and peripheral T cells on day 14 (p = 0.004) and day 30 (p = 0.004). Higher alteration of the CD8+/CD4+ ratio on day 14 indicated a longer OS (p = 0.010). Conclusions: Our modified TIL therapy regimen demonstrated manageable safety, and TILs could survive and proliferate without IL-2 intravenous administration, showing potent efficacy in patients with advanced gynecologic cancer. Trial registration: NCT04766320, Jan 04, 2021.

Original languageEnglish (US)
Article number207
JournalBMC medicine
Volume22
Issue number1
DOIs
StatePublished - Dec 2024

Keywords

  • Gynecologic malignancies
  • Interleukin-2
  • Lymphodepletion
  • Tumor-infiltrating lymphocyte

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer'. Together they form a unique fingerprint.

Cite this